Full Press Release Details
TACTILE MEDICAL ANNOUNCES ACQUISITION OF AFFLOVEST
expands the Company's position as a leader in treating patients with underserved chronic conditions in the
aligns with Tactile Medical's growth & margin goals, including 20%+ revenue growth, gross margins above 70% and expanding
adjusted EBITDA margins
MINNEAPOLIS, MN, September 8, 2021 - Tactile Systems Technology,
Inc. ("Tactile Medical" or the "Company") (Nasdaq: TCMD), a medical technology company focused on developing medical
devices for the treatment of underserved chronic diseases at home, today announced it has acquired the assets of the AffloVest respiratory
therapy business from International Biophysics Corporation, a privately-held company which developed and manufactures AffloVest.
AffloVest is a portable, wearable vest that treats patients with chronic
respiratory conditions such as COPD-associated breathing conditions like bronchiectasis, or conditions resulting from neuromuscular disorders
and cystic fibrosis, by managing airway clearance. AffloVest is the first truly portable, battery-powered, High Frequency Chest Wall Oscillation
(HFCWO) device. Its use has been shown to reduce antibiotic use, emergency room visits and hospitalizations.
Management Commentary
"The addition of AffloVest represents an ideal strategic fit
for Tactile Medical as it aligns well with our focus of treating patients with underserved chronic conditions in the home," said
Dan Reuvers, President and CEO of Tactile Medical. "We expect to promote AffloVest's patented, portable design, demonstrated
clinical outcomes, and established reimbursement within the Durable Medical Equipment (DME) channel to drive AffloVest to contribute to
our overall company goal of 20%+ revenue growth going forward. Like lymphedema, the chronic pulmonary disease market represents a large,
and still underpenetrated opportunity. Importantly, multiple members of our management team have significant experience in this category,
which gives us confidence in our ability to execute our commercial strategy for AffloVest. We look forward to welcoming the AffloVest
sales team to Tactile Medical and intend to maintain their strategy of partnering with DME companies to promote the proven therapy. The
sales representatives at these DME companies are uniquely positioned to provide valuable access to chronic respiratory providers and patients
through their complementary product and service offerings such as oxygen, nebulizers and ventilators."
Reuvers continued, "Longer term, we believe adding a mobile,
wearable therapy to our portfolio invites synergy within our R&D roadmap as we advance our goals within ease-of-use and digital engagement.
We believe this is a compelling transaction as it expands Tactile Medical's annual addressable market opportunity in the U.S. to
more than $10 billion, fits our long-term revenue and margin growth profile, enhances our long-term profitability, and is expected to
generate an attractive return on investment."
About Tactile Systems Technology, Inc. (DBA Tactile Medical)
Tactile Medical is a leader in developing and marketing at-home
therapy devices that treat chronic swelling conditions such as lymphedema and chronic venous insufficiency. Tactile Medical's Mission
is to help people suffering from chronic diseases live better and care for themselves at home. The Company's unique offering includes
advanced, clinically proven pneumatic compression devices, as well as continuity of care services provided by a national network of product
specialists and trainers, reimbursement experts, patient advocates and clinicians. This combination of products and services ensures that
tens of thousands of patients annually receive the at-home treatment necessary to better manage their chronic conditions. Tactile
Medical takes pride in the fact that its solutions help increase clinical efficacy, reduce overall healthcare costs and improve the
quality of life for patients with chronic conditions.
About International Biophysics Corporation
International Biophysics Corporation brings to market innovative, disruptive
medical devices and technologies that improve treatment therapies and patient outcomes. The company has a strong history of developing
and launching innovative and disruptive technologies. Centered in a precision ISO 13485 certified, FDA registered, state of the art manufacturing
facility, International Biophysics Corporation continues to research and develop advanced solutions for physicians and patients.
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements, including,
without limitation, statements related to the Company's growth and margin goals and related to the acquisition of AffloVest,
such as expected revenues and revenue growth of AffloVest and the related impact on the Company's revenues, the impact on the
Company's long-term profitability profile, AffloVest's expected gross margins and adjusted EBITDA margins, the expected
accretive impact of the acquisition, the results of anticipated leveraging and commercial strategies, including potential market
share gains, the annual addressable market opportunity for AffloVest and the Company, and the expected net leverage ratio of
the Company in the future, as well as attractive return on investment. Forward-looking statements are generally identifiable by the
use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," "continue,"
"confident," "outlook," "guidance," "project," "goals," "look
forward," "poised," "designed," "plan," "return," "focused,"
"prospects" or "remain" or the negative of these words or other variations on these words or comparable
terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject
to numerous factors and uncertainties outside of the Company's control that can make such statements untrue, including, but
not limited to, whether and when the Company will be able to realize the expected financial results and accretive effect of the
acquisition, and how customers, competitors, suppliers and employees will react to the acquisition, the impacts of the COVID-19
pandemic on the Company's business, financial condition and results of operations; the course of the COVID-19 pandemic and its
impact on general economic, business and market conditions; the Company's inability to execute on its plans to respond to the
COVID-19 pandemic; the adequacy of the Company's liquidity to pursue its business objectives; the Company's ability to
obtain reimbursement from third party payers for its products; loss or retirement of key executives, including prior to identifying
a successor; adverse economic conditions or intense competition; loss of a key supplier; entry of new competitors and products;
adverse federal, state and local government regulation; technological obsolescence of the Company's products; technical
problems with the Company's research and products; the Company's ability to expand its business through strategic
acquisitions; the Company's ability to integrate acquisitions and related businesses; price increases for supplies and
components; the effects of current and future U.S. and foreign trade policy and tariff actions; or the inability to carry out
research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially
are discussed in the Company's filings with the SEC. Investors and security holders are urged to read these documents free of
charge on the SEC's website at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events or otherwise.
Non-GAAP Financial Measures
This press release includes the non-GAAP financial measure of expected
adjusted EBITDA margin of AffloVest, which differs from financial measures calculated in accordance with U.S. generally accepted accounting
principles ("GAAP").
Expected adjusted EBITDA margin in this release represents AffloVest's
expected net income, plus interest expense or less interest income, less income tax benefit or plus income tax expense, plus depreciation
and amortization, plus stock-based compensation expense, plus impairment charges and inventory write-offs, plus litigation defense costs,
plus executive transition costs, plus transaction costs, plus purchase accounting charges, plus business optimization expenses, and plus
other restructuring and integration costs, on a percentage of revenue basis. This non-GAAP financial measure is presented because the
Company believes it is a useful indicator of AffloVest's projected operating performance. Such non-GAAP financial measure is supplemental
only, and should not be considered superior to, as a substitute for, or as an alternative to, and should be considered in conjunction
with, net margin. This non-GAAP financial measure may differ from similar measures used by other companies.
The Company cannot reconcile AffloVest's expected adjusted EBITDA
margin to expected net income margin without unreasonable effort because certain items that impact net income and other reconciling metrics
are out of the Company's control and/or cannot be reasonably predicted at this time. Such unavailable information could have a significant
impact on the GAAP financial results.